Report: Gilead Sets US Price For Antiviral Treatment At More Than $500 Per Dose
Gilead Sciences has controversially set the price of its COVID-19 treatment drug, remdesivir, at $520 per vial in the United States, which totals about $3,120 for the typical course of treatment, reported Squawk Box.
- Gilead had previously agreed to donate its existing supplies of remdesivir through the end of June.
- This new pricing released is raising some eyebrows, as it is higher in the U.S. than in other developed countries, where the price is $2,340 for the entire course of treatment.
- Gilead claims that this difference is due to the way in which the drug discounting system works in the U.S.
- The company said that since the drug reduces hospital stays by four days, they are saving $12,000 per patient.
- Therefore, Gilead argues that they are actually offering a great discount on the drug.
Daniel O’Day, the Chairman & CEO of Gilead Sciences, said in an open letter: “As the world continues to reel from the human, social and economic impact of this pandemic, we believe that pricing remdesivir well below value is the right and responsible thing to do.”